Literature DB >> 23404519

Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction.

Wayne Laurence Monsky1, Chris Molloy, Bedro Jin, Timothy Nolan, Dayantha Fernando, Shaun Loh, Chin-Shang Li.   

Abstract

PURPOSE: Malignancies may cause urinary tract obstruction, which is often relieved with placement of a percutaneous nephrostomy tube, an internal double J nephro-ureteric stent (double J), or an internal external nephroureteral stent (NUS). We evaluated the affect of these palliative interventions on quality of life (QoL) using previously validated surveys.
METHODS: Forty-six patients with malignancy related ureteral obstruction received nephrostomy tubes (n = 16), double J stents (n = 15), or NUS (n = 15) as determined by a multidisciplinary team. QoL surveys were administered at 7, 30, and 90 days after the palliative procedure to evaluate symptoms and physical, social, functional, and emotional well-being. Number of related procedures, fluoroscopy time, and complications were documented. Kruskal-Wallis and Friedman's test were used to compare patients at 7, 30, and 90 days. Spearman's rank correlation coefficient was used to assess correlations between clinical outcomes/symptoms and QoL.
RESULTS: Responses to QoL surveys were not significantly different for patients receiving nephrostomies, double J stents, or NUS at 7, 30, or 90 days. At 30 and 90 days there were significantly higher reported urinary symptoms and pain in those receiving double J stents compared with nephrostomies (P = 0.0035 and P = 0.0189, respectively). Significantly greater fluoroscopy time was needed for double J stent-related procedures (P = 0.0054). Nephrostomy tubes were associated with more frequent minor complications requiring additional changes.
CONCLUSION: QoL was not significantly different. However, a greater incidence of pain in those receiving double J stents and more frequent tube changes in those with nephrostomy tubes should be considered when choosing palliative approaches.

Entities:  

Mesh:

Year:  2013        PMID: 23404519      PMCID: PMC4601638          DOI: 10.1007/s00270-013-0571-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  16 in total

1.  A SAS(®) macro implementation of a multiple comparison post hoc test for a Kruskal-Wallis analysis.

Authors:  Alan C Elliott; Linda S Hynan
Journal:  Comput Methods Programs Biomed       Date:  2010-12-10       Impact factor: 5.428

2.  Quality of life in long-term survivors of bladder cancer.

Authors:  Veerasathpurush Allareddy; Julianna Kennedy; Michele M West; Badrinath R Konety
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

3.  Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization.

Authors:  Brandt C Wible; William S Rilling; Peter Drescher; Robert A Hieb; Kia Saeian; Constantine Frangakis; Yong Chen; Daniel Eastwood; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2010-06-04       Impact factor: 3.464

4.  Psychometric analysis of the Functional Assessment of Cancer Therapy-General (FACT-G) scale in a rural sample.

Authors:  P Winstead-Fry; A Schultz
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

5.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

6.  Symptoms arising from Double-J ureteral stents.

Authors:  S G Pollard; R Macfarlane
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

7.  Nephrostomy tube or 'JJ' ureteric stent in ureteric obstruction: assessment of patient perspectives using quality-of-life survey and utility analysis.

Authors:  H B Joshi; S Adams; O O Obadeyi; P N Rao
Journal:  Eur Urol       Date:  2001-06       Impact factor: 20.096

8.  Percutaneous nephrostomy: techniques, indications, and results.

Authors:  D P Stables
Journal:  Urol Clin North Am       Date:  1982-02       Impact factor: 2.241

Review 9.  To stent or not to stent: an evidence-based approach to palliative procedures at the end of life.

Authors:  Sydney M Dy; Stephanie M Harman; Ursula K Braun; Lynn J Howie; Patricia F Harris; Robert L Jayes
Journal:  J Pain Symptom Manage       Date:  2012-04       Impact factor: 3.612

Review 10.  Data for cancer comparative effectiveness research: past, present, and future potential.

Authors:  Anne-Marie Meyer; William R Carpenter; Amy P Abernethy; Til Stürmer; Michael R Kosorok
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

View more
  9 in total

Review 1.  Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction.

Authors:  Linda Hsu; Hanhan Li; Daniel Pucheril; Moritz Hansen; Raymond Littleton; James Peabody; Jesse Sammon
Journal:  World J Nephrol       Date:  2016-03-06

2.  Squamous cell carcinoma of skin due to prolonged indwelling percutaneous nephrostomy catheter.

Authors:  Ashish Sharma; Vishwajeet Singh; Rahul Janak Sinha; Samarth Agarwal
Journal:  BMJ Case Rep       Date:  2019-05-24

3.  Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment.

Authors:  Samuel Stephen Folkard; Srijit Banerjee; Richard Menzies-Wilson; Joseph Reason; Evangelos Psallidas; Elliot Clissold; Ahmad Al-Mushatat; Saurabh Chaudhri; James Stephen Arthur Green
Journal:  Int Urol Nephrol       Date:  2020-04-22       Impact factor: 2.370

4.  Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients.

Authors:  Kao-Lang Liu; Bo-Ching Lee; Jian-De Ye; Yu-Hsuan Chang; Chin-Chen Chang; Kuo-How Huang; Yuan-Ju Lee; Yeun-Chung Chang
Journal:  Eur Radiol       Date:  2018-07-04       Impact factor: 5.315

Review 5.  [Management of ureteral obstruction : Value of percutaneous nephrostomy and ureteral stents].

Authors:  C Netsch; B Becker; A J Gross
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

6.  Can preoperative ureteral stents reduce the incidence of ureteral stricture after radiotherapy in patients with cervical cancer?

Authors:  Liang Liu; Chunhong Yu; Fuzhen Sun; Tao Yang; Dong Wei; Gang Wang; Shoubin Li; Junjiang Liu
Journal:  BMC Urol       Date:  2022-07-18       Impact factor: 2.090

7.  10-Year Experience with Reinforced Ureteral Stents for Malignant Ureteral Obstruction.

Authors:  Benoît Vogt; Laure-Hélène Blanchet
Journal:  Res Rep Urol       Date:  2021-08-14

8.  [Comparison of catheter-associated quality of life in external urinary diversion: nephrostomy vs. suprapubic catheter].

Authors:  A Wiedemann; M Weinhofer; J Stein; C Linné; R Kirschner-Hermanns; A Schorn; A Wagner; V Moll; U Unger; J Salem; T Liebald; A Bannowsky; S Wirz; E Brammen; H-J Heppner
Journal:  Urologe A       Date:  2022-01-13       Impact factor: 0.639

Review 9.  Stents for malignant ureteral obstruction.

Authors:  Kristina Pavlovic; Dirk Lange; Ben H Chew
Journal:  Asian J Urol       Date:  2016-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.